AzTrials
AzTrials

Pain Postoperative, Intraoperative HemorrhagePhase 4NCT02013570

Efficacy of Peritonsillar Dexmedetomidine Infiltration for Postadenotonsillectomy Pain

A Phase 4 study testing Dexmedetomidine in people with Pain Postoperative, Intraoperative Hemorrhage, run by TC Erciyes University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the present study is the clinical assessment of the efficacy of preincisional peritonsillar infiltration of dexmedetomidine on postoperative pain relief in children undergoing adenotonsillectomy. Read more about this study

Who is it for?
Ages 3 to 9 years
What is being tested?
Dexmedetomidine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
71 participants
Where
No sites listed yet
Study dates
Sep 2013to Dec 2013
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 9 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • children aged 3-9 years American Society of Anesthesiologists 1-2 status, scheduled for adenotonsillectomy

Who cannot join

  • Children with systemic disease, metabolic and endocrin disorders, growth developmental and motor-mental retardation, those who had a history of allergy to any of the study drugs, peritonsillar abscess, hypertension, psychiatric and epileptic disorders, chronic pain syndrome, and those who received analgesics within 24 h prior to surgery were excluded from study.

About this study

The purpose of the present study is the clinical assessment of the efficacy of preincisional peritonsillar infiltration of dexmedetomidine on postoperative pain relief in children undergoing adenotonsillectomy.

Read the detailed description

Background:Tonsillectomy is a common and painful procedure in children, often performed on an outpatient basis. Tonsillectomy is often associated with intraoperative bleeding and postoperative severe pain. Different methods such as drugs (nonsteroidal antiinflammatory drugs , opioids, corticosteroids ), adjustment of surgical technique and peroperative local anaesthetic infiltration have been used to reduce pain. It is known that pain after adenotonsillectomy or analgesic usage may lead to unwanted effects. For example, nonsteroidal antiinflammatory drugs may interfere with bleeding and opioids may cause respiratory depression, sedation or nausea and vomiting. There are some reported complications seen infiltrations of local anaesthetics into tonsillar and adenoid beds. No studies have assessed the effects of peritonsillar dexmedetomidine infiltration. Dexmedetomidine is a centrally acting sympatholytic agent that has intrinsic effect of regional anesthesia with amid anesthetic.Because of its analgesic and sedating activity, dexmedetomidine has been used previously as an nasal premedication in patients undergoing tonsillectomy, but its use, as a peritonsillar infiltration has not been evaluated. Dexmedetomidine is a highly selective alfa-2 adrenoreceptor agonist recently introduced to anesthesia practice producing dose-depended sedation, anxiolysis, and analgesia (involving spinal and supraspinal sites), without respiratory depression. Also Alpha-2 adrenergic agonists have peripheral analgesic effects. Therefore, this study was designed to compare the effects of preincisional, dexmedetomidine 2µg/kg peritonsillar infiltration by peritonsillar normal saline grup on intraoperative bleeding and hemodynamics, postoperative recovery including pain, sedation, nausea and vomiting in pediatric patients undergoing adenotonsillectomy, and the recording of any adverse effects that might develop during the 24-h study period.

Methods: Seventy patient were randomized into two groups: group S peritonsillar 2ml normal saline (1 ml per tonsil), group D 2mikro gram/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil).

After institutional Ethics Committee approval and parents written consent, 70 children aged 3-9 years, American Society of Anesthesiologists 1-2 status, scheduled for adenotonsillectomy were enrolled in this randomized, prospective, triple-blind clinical study. Children with systemic disease, metabolic and endocrin disorders, growth developmental and motor-mental retardation, those who had a history of allergy to any of the study drugs, peritonsillar abscess, hypertension, psychiatric and epileptic disorders, chronic pain syndrome, and those who received analgesics within 24 h prior to surgery were excluded from study.

The children were unpremedicated. Anaesthesia was induced with sevoflurane 8% and nitrous oxide 70% in oxygen or intravenous induction with propofol (2,5-3 mg/kg). After induction rocuronium 0,6 mg/kg was administered for muscle relaxation and fentanyl 1 µg/kg before tracheal intubation. Anaesthesia was maintained with sevoflurane 2-3% and nitrous oxide 30% in oxygen. After intubation children were randomized into two groups:Group D 2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil), Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration. For the infiltration, all injections were performed through the tonsillar capsule and anterior plica. After the infiltration, a minimum of 3 min was allowed for the onset of action of dexmedetomidine before adenotonsillectomy. Adenotonsillectomy was performed with snare technic by the same surgeon in all cases. Heart rate, arterial pressure and oxygen saturations (SpO2) were recorded at 10 min interval during operation.All patients received metoclopropamide 0,2 mg/kg i.v. before end of the surgery. After extubation the patients were taken to the postanesthesia care unit where an anesthetist and nurses who were unaware of the study drug observed the patients.

Modified Hannallah pain scale (observational pain scores-OPS), nausea, vomiting, bleeding, rescue analgesia, sedation and Aldrete scores were recorded on arrival in the postanesthesia care unit, at 15th, 30th, 60th, 90th and 120th min. Patient with OPS scores >4, for a patient request for pain medication, received 1mg/kg Tramadol drop as supplementary analgesia. The first analgesic requirement time recorded. Children vomiting twice or more in PACU received additional antiemetic drug (metoclopropamide 0,2 mg/kg i.v.). Agitation was measured with Pediatric anesthesia emergence delirium scale. Patients with an Aldrete score of 9 were transferred to the postoperative surgical ward.

Pain, nausea and vomiting, bleeding and sedation were assessed in the postoperative surgical ward at0,2,4,6h follow-up by the nurses who were trained fort he use of scores involved. Analgesic requirement were recorded. Pain was measured at rest and with swallowing. All patients were discharged at the and of the day and stayed home at night. Before the discharge, parents were given a prescription for acetaminophen (15 mg/kg oral dose) to be given when needs to analgesia. Postoperative pain during the first 24 h was assessed using a four-point scale: 0=no pain, 1=mild pain, 2=moderate pain, 3=severe pain by questioning their parents. Patients were interviewed on the day after surgery to asses the postoperative pain, vomiting, bleeding and rescue analgesia. Family satisfaction was assessed as follows: 1=poor; 2=good; 3=perfect.

Being tested
Dexmedetomidine
Keywords
postoperative pain; dexmedetomidine; adenotonsillectomy
Medical subject headings
Pain, Postoperative, Blood Loss, Surgical

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    Also called Precedex

    2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),

Study groups in NCT02013570
Study groupRoleWhat they receive
DexmedetomidineActive comparatorGroup S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
Receives: Drug: Dexmedetomidine
Normal saline, postoperative painPlacebo comparatorGroup S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
Receives: Drug: Dexmedetomidine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. post adenotonsillectomy pain

    Modified Hannallah pain scale, nausea, vomiting, bleeding, rescue analgesia, sedation and Aldrete scores were recorded on arrival in the postanesthesia care unit, at 15th, 30th, 60th, 90th and 120th min. Patient with pain scores >4, for a patient request for pain medication, received 1mg/kg Tramadol drop as supplementary analgesia. The first analgesic requirement time recorded. Agitation was measured with Pediatric anesthesia emergence delirium scale. Patients with an Aldrete score of 9 were transferred to the postoperative surgical ward.

    Pain, nausea and vomiting, bleeding and sedation were assessed in the postoperative surgical ward. Analgesic requirement were recorded. Pain was measured at rest and with swallowing. All patients were discharged at the end of the day and stayed home at night. Postoperative pain during the first 24 h was assessed using a four-point scale. Patients were interviewed on the day after surgery to ases.

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2013 (estimated)
  2. Study startSep 2013
  3. Primary completionDec 2013
  4. Study completionDec 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
71 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02013570
Sponsor's protocol ID
2013/556
Status last verified
Sep 2013
First submitted
2 Dec 2013
Last updated
17 Dec 2013
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Dexmedetomidine in people with Pain Postoperative, Intraoperative Hemorrhage, run by TC Erciyes University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

post adenotonsillectomy pain (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in